BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the appointment of Dr. Randolph Ford to its Strategic Advisory team to enhance its data analytics and AI capabilities during the commercial acceleration of its early cancer detection technology. Mr. Rashid Ahmed Bux, CEO and President of BioMark...
2023-11-14 8:30 AM EST
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its wholly owned laboratory subsidiary, BioMark Diagnostic Solutions Inc ("BDS"), has been awarded non-dilutive funding of CAD $231,000 from the City of Quebec through its Vision Entrepreneuriale Québec 2026 to accelerate...
2023-11-07 8:30 AM EST
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its abstract has been accepted for poster presentation at the upcoming San Antonio Brest Cancer Symposium (SABCS) taking place December 5-9, 2023 in San Antonio, Texas.The abstract entitled "Early Detection of Breast Cancer using Targeted...
2023-10-24 8:30 AM EDT
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that Vice Admiral Kevin Cosgriff will be joining BioMark's Advisory team to support its innovation and investment strategy. Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics, says: "We are at a critical inflection point in the...
2023-08-30 8:30 AM EDT
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Japan Patent Office (JPO) has issued Divisional Patent Application N° 7311659 titled "Methods of detecting lung cancer" using urine biomarkers. The issued patent belongs to a larger family of patents on the Company's biomarker panel for detecting lung...
2023-08-08 8:30 AM EDT
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - July 25, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity. The Company is unaware of any material change in its operations that would account for the recent increase in market activity and higher volume of daily trading."BioMark has been making significant strides in getting ready for clinical laboratory...
2023-07-25 8:30 AM EDT
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that its latest leading-edge research was presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting that is currently taking place in Chicago, Illinois. The poster entitled "Large retrospective validation study of metabolomic biomarkers for resectable...
2023-06-05 8:30 AM EDT
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,656,229 which was filed as a provisional on June 26, 2015 and titled Method of Detecting Lung Cancer. The issued patent belongs to a larger family...
2023-05-31 8:30 AM EDT
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its abstract have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, Illinois.The abstract entitled, "Large Scale Retrospective Validation of Plasma Metabolite Panel for Early-Stage...
2023-05-03 8:30 AM EDT
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this week suggests that Pulmonary Neuroendocrine Tumors (NETs) are reprogramming their metabolism as reflected by the presence of a panel of distinct metabolic biomarkers. A logistic regression model constructed with 8 metabolites was able...
2023-03-16 8:30 AM EDT
BioMark Provides Third Quarter Operational Update and 2023 Outlook
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2022, as well as outlook for 2023.Business Update Highlights"We are excited to share our Q3 results which demonstrates BioMark's efforts to solidify its robust technology platform and to accelerate commercialization...
2023-03-01 8:30 AM EST
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS"), is receiving advisory services and non-dilutive funding of up to CAD $185,900 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). ...
2023-02-07 8:30 AM EST
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer.As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce today that enrollment for...
2023-01-11 8:30 AM EST
BioMark Provides Business Update and Second Quarter Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the "Warrants") issued in relation to a private placement financing that closed on December 13, 2019 on a continuing effort to improve corporate value for its shareholders. The...
2022-11-28 8:30 AM EST
BioMark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle. The study published as part of the special issue of Cancers "Novel Techniques and Technology for...
2022-10-27 8:30 AM EDT
The US Patent Office Grants BioMark Additional Patent for Its Liquid Biopsy Technology
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing and measuring treatment response for various forms of hard to detect and treat cancer. The technology can also be...
2022-09-20 8:30 AM EDT
BioMark to Present Validation Data of Its Multianalyte Metabolite Panel for Lung Cancer Screening at the ESMO Congress 2022
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it's abstract titled "Metabolomic Profiling for the Early Detection of Lung Cancer" has been accepted for presentation at the upcoming ESMO Congress 2022 taking place on September 9 – 13, 2022 in Paris, France.The Company will be presenting...
2022-09-08 8:30 AM EDT
BioMark Selected by the Medical Alley and Investissement Quebec to Join the Us Go-To-Market Accelerator
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") have been selected among the top 10 innovative companies to participate in the 2022 MedTech & Digital Health U.S. Market Access Program for Quebec companies with Medical Alley. The U.S. Market Access Program is a...
2022-09-01 8:30 AM EDT
BioMark Provides First-Quarter 2022 Financial Results and Operational Update
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 2022."We closed out the quarter with great milestone accomplishment that reflect the ongoing momentum we have built towards our commercialization efforts for our blood-based assay designed for early detection and screening of lung...
2022-08-30 8:30 AM EDT
BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-year ended March 31, 2022 "We closed out the year with great milestone accomplishment that reflects the ongoing momentum we have built toward our goal to commercialize our blood-based assay for the early...
2022-07-14 8:30 AM EDT